has a long half-life allowing for once-daily dosing in treatment-naive patients and has less pharmacokinetic variability compared with other HIV INSTIs. For treatment-naive patients, dolutegravir ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback